Germany's MediClin H1 profit rises on stable core business, cost controls

MEDICLIN AG

30/07/2026 12:13

Overview
Germany healthcare provider's H1 2026 revenue rose 5% yr/yr to EUR 386.4 mln
Group EBIT for H1 2026 increased to EUR 26.6 mln from EUR 22.4 mln
Company cites stability in core business and cost management for improved earnings

Outlook
MediClin expects full-yr revenue to rise by 3.5% to 6.5%
Company sees full-yr group EBIT between EUR 57.0 mln and EUR 72.0 mln

Result Drivers
CORE BUSINESS STABILITY - Co said stability in core business areas supported H1 2026 results
COST MANAGEMENT - Co attributed improved earnings to efficient cost management
POST-ACUTE SEGMENT GROWTH - Revenue in the Post-Acute segment increased, with lower cost of materials ratio aiding segment EBIT

Company press release: ID:nEQ7P7ncda

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Sales
 
EUR 386.40 mln
 
H1 EBIT
 
EUR 26.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Mediclin AG is €6.20, about 49.8% above its July 29 closing price of €4.14
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago

Reuters Recommended Reads
July 29 - France's Clariane H1 revenue rises 4.6% organically, EBITDA margin improves
July 29 - France's Emeis H1 revenue rises on higher average occupancy rates
July 28 - Germany's Medios cuts 2026 EBITDA outlook on pharma supply price pressure

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)